A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine protects at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when immunised four weeks before birth
- Maternal antibodies passed through the placenta safeguard newborns from birth
- Protection possible with 2-week gap before early delivery
- Vaccination in the third trimester still offers meaningful protection for infants
Strong evidence from current research
The effectiveness of the pregnancy RSV vaccine has been established through a extensive research programme carried out throughout England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month timeframe, providing comprehensive and reliable evidence of the vaccine’s real-world impact. The study’s conclusions have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scope of this study provides healthcare professionals and expectant parents with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This clear distinction underscores the vaccine’s vital importance in reducing the risk of serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology captured actual clinical results rather than controlled laboratory conditions, providing tangible evidence of how the vaccine works when administered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and its dangers
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection produces deep inflammation in the lungs and airways, making it perilously hard for affected infants to feed and breathe adequately. Parents often witness their babies struggling visibly, their chests heaving as they work to get sufficient oxygen into their damaged lungs. Whilst the majority of babies recover with palliative treatment, a limited though important group succumb from RSV-related complications each year, making immunisation programmes a essential public health objective for safeguarding the youngest and most at-risk individuals in the population.
- RSV produces lung inflammation, resulting in serious respiratory problems in babies
- Approximately half of newborns contract the infection in their first few months of life
- Symptoms span from mild colds to serious chest infections that threaten life needing hospital treatment
- More than 20,000 UK babies need serious hospital treatment for RSV annually
- Few infants succumb to RSV related complications each year in the UK
Adoption rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have stressed the significance of pregnant women receiving their jab at the ideal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for guaranteeing newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers nearly 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to increase the antibodies transferred to their babies via the placenta.
The communication from public health bodies remains clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has reassured pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach recognises the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of severe infection.
Regional variations in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These regional differences reflect differences across healthcare infrastructure, engagement approaches, and community involvement initiatives, though the overall statistics shows robust and reliable protection regardless of geographical location.
- NHS trusts launching varied communication campaigns to reach expectant mothers
- Inconsistencies across regions in vaccination coverage levels throughout England require targeted improvement
- Local healthcare systems modifying schemes to meet local requirements and situations
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness translates into tangible benefits for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the launch of this safeguarding intervention, the 80% reduction in admissions means thousands of infants spared from critical disease. Parents no more face the troubling prospect of watching their newborns gasping for air or labour to feed, symptoms that mark serious RSV disease. The vaccine has markedly changed the picture of neonatal respiratory health, giving expectant mothers a proactive tool to shield their most vulnerable children during those vital initial period.
For families like that of Malachi, whose acute RSV infection caused profound brain damage, the vaccine’s availability carries profound emotional significance. His mother’s advocacy for the jab underscores the transformative consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to women in pregnancy during their third trimester, transforming what was once an inevitable seasonal threat into a manageable risk.